MURRAY HILL, N.J.--(BUSINESS WIRE)--The Board of Directors of C. R. Bard, Inc. (NYSE:BCR) today authorized the repurchase of up to $500 million of the company’s common stock. This is in addition to approximately $205 million remaining under the prior authorization announced in June 2015. Share repurchases will be made from time-to-time in the open market or through privately negotiated transactions.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.